Answers are grounded in this paper and cite their sources.
OBJECTIVE: This study examined longitudinal changes in cognitive functioning among the pediatric multiple sclerosis (MS) population in the largest cohort to date representing the U.S. Network of Pediatric MS Centers. BACKGROUND: Pediatric MS is a rare variant of the adult-onset neurologic disease diagnosed under the age of 18 years, with an estimated frequency of 0.5 to 1.0 per 100,000. Studies have found that approximately one-third of children and adolescents with MS have some degree of cognitive impairment. Less is known concerning change in cognitive functioning over time, but initial studies have suggested a significant risk for decline over relatively short time periods. DESIGN/METHODS: Sixty-seven (67) individuals with pediatric MS (n=62) or clinically isolated syndrome (CIS, n=5), ranging in age from 8 to 17 years of age (mean age ± standard deviation = 14.37 ± 2.02), completed initial and follow-up neuropsychological testing after an average of 1.64 ± 0.63 years. The nine tests administered measure general intellect, attention and working memory, verbal memory, visuomotor integration, language, and executive functioning. RESULTS: Rate of cognitive impairment (defined as having one-third or more test scores in the impaired range) was 37% at baseline and 33% at follow-up, generally consistent with previous reports. Tests most commonly impaired were those for measures of visuomotor integration, speeded processing, and attention. In contrast to prior observations, most children and adolescents tested did not decline over two years, nor was there any clear pattern or signal for impairment on specific measures. CONCLUSIONS: Findings suggest that over short time frames, stable or even improved performances on measures of cognitive ability can occur in pediatric MS. Rather than leading to decline, pediatric MS may instead adversely affect cognitive functioning by interfering with expected age-appropriate gains. Study Supported by: The Lourie Foundation, Inc., National Multiple Sclerosis Society (10020073405), NIH R01N5071463, and the Slomo and Cindy Silvian Foundation.
No takes yet. Share an insight, caveat, or question.
Krupp et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: